Develop a new therapy to treat triple negative breast cancer using immunotherapy and chemotherapy.
Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer
This study is testing a new treatment for triple negative breast cancer that combines immunotherapy and chemotherapy to better fight the cancer while causing fewer side effects, aiming to help patients by targeting the cancer's root causes and boosting their immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11045945 on NIH RePORTER |
What this research studies
This research aims to create a novel treatment for triple negative breast cancer by combining immunotherapy with chemotherapy to enhance effectiveness and reduce side effects. The approach focuses on targeting cancer stem cells, which are responsible for cancer initiation and recurrence. By suppressing a specific oncogene, the therapy seeks to improve immune response against tumors while minimizing damage to healthy tissues. Patients may benefit from a more effective treatment option that addresses both tumor growth and immune system activation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have not responded well to existing therapies.
Not a fit: Patients with non-breast cancers or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for triple negative breast cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in combining immunotherapy with targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Fang, Deyu — Northwestern University at Chicago
- Study coordinator: Fang, Deyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.